Polycythemia Vera Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therape

DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom, and Japan.

Discover which therapies are expected to grab the Polycythemia Vera Market Share @ Polycythemia Vera Market Outlook- https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Polycythemia Vera Market Report
• In May 2025, Merck Sharp & Dohme LLC conducted a study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator.
• In May 2025, Incyte Corporation announced a phase 1/2 study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
• The United States contributed to the largest prevalent population of Polycythemia Vera, acquiring ~57% of the 7MM in 2024. Whereas EU4 and the UK, and Japan accounted for around 32% and 11% of the total population share, respectively, in 2024.
• The total number of prevalent cases of Polycythemia Vera in the United States was around 182,010 cases in 2024.
• Among the EU4 countries, Germany accounted for the largest number of Polycythemia Vera cases based on symptoms, whereas Spain accounted for the lowest number of cases in 2024.
• According to DelveInsight estimates, there were around 72,810 cases of asymptomatic and 109,210 cases of symptomatic Polycythemia Vera in the United States in 2024. The prevalence is projected to increase during the forecasted period.
• In Japan among the age-specific data, the 65-74 years of age group was found to be most prevalent in Polycythemia Vera, accounting for nearly 30% of the total cases in 2024.
• In 7MM, approximately 56% of the patient share is attributed to males, whereas only 44% of females suffer from Polycythemia Vera.
• The leading Polycythemia Vera Companies such as Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
• Promising Polycythemia Vera Therapies such as Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others

Stay ahead in the Polycythemia Vera Therapeutics Market with DelveInsight's Strategic Report @ Polycythemia Vera Market Outlook- https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polycythemia Vera Epidemiology Segmentation in the 7MM
• Total Prevalence of Polycythemia Vera
• Prevalent Cases of Polycythemia Vera by severity
• Gender-specific Prevalence of Polycythemia Vera
• Diagnosed Cases of Episodic and Chronic Polycythemia Vera

Download the report to understand which factors are driving Polycythemia Vera Epidemiology trends @ Polycythemia Vera Prevalence- https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Polycythemia Vera Drugs
• JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis
JAKAFI/JAKAVI is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases. It is approved for treating adult patients resistant to or intolerant of hydroxyurea. Incyte's flagship product, Jakafi, received approval as second-line therapy for Polycythemia Vera patients in December 2014 in the United States, followed by approvals in both the EU and Japan in 2015.

• BESREMi (ropeginterferon alfa-2b): PharmaEssentia/AOP Orphan Pharmaceuticals
PharmaEssentia's BESREMi, a monopegylated proline interferon is a new entrant for first as well as more advanced-line Polycythemia Vera patients without symptomatic splenomegaly; it is one of the first to be approved for condition. BESREMi was approved in November 2021 in the US; meaningful sales began in 2022. Before the US launch, the drug was approved in the EU in 2019 and has been available in Germany, France, and the UK since 2020, whereas in April 2022, the drug was approved for reimbursement by Italy's National Health Service (SSN). Later in March 2023, the Ministry of Health, Labor, and Welfare (MHLW) approved BESREMi for the treatment of Polycythemia Vera (limited to cases where existing treatments are inadequate or inappropriate)

Emerging Polycythemia Vera Drugs
• Rusfertide (PTG-300): Protagonist Therapeutics
Rusfertide is a novel injectable synthetic mimetic of the natural hormone hepcidin that offers greater potency, solubility, and stability, which translates to better in vivo pharmacokinetics and pharmacodynamics characteristics and manufacturability in comparison to the natural hormone. In December 2024, the final results of rusfertide from the Phase II REVIVE trial were presented at the ASH (4559) meeting. The data demonstrated that rusfertide when added to therapeutic phlebotomy with or without cytoreductive therapy, effectively controlled erythrocytosis, provided long-term durable control of hematocrit, and reduced the need for therapeutic phlebotomy in patients with Polycythemia Vera.

• Bomedemstat (MK-3543 [IMG-7289]): Merck (Imago BioSciences)
Bomedemstat is an investigational small molecule, irreversible Lysine-specific Demethylase 1 (LSD1) inhibitor being developed by Merck. Bomedemstat is being evaluated in a wide range of myeloproliferative neoplasms, including essential thrombocythemia, myelofibrosis, and Polycythemia Vera. Currently, an ongoing investigator-sponsored Phase III trial evaluates bomedemstat in Polycythemia Vera patients.

To learn more about Polycythemia Vera treatment guidelines, visit @ Polycythemia Vera Treatment Market Landscape- https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polycythemia Vera Therapies and Key Companies
• Rusfertide (PTG-300): Protagonist Therapeutics
• Givinostat (ITF2357): Italfarmaco
• Bomedemstat: Imago BioSciences
• SLN124: Silence Therapeutics
• Sapablursen: Ionis Pharmaceutical
• PPMX-T003: Perseus Proteomics
• PTG-300: Protagonist Therapeutics, Inc.
• SLN124: Silence Therapeutics plc
• Hydroxyurea: Novartis
• Ropeginterferon alfa-2b: PharmaEssentia
• PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG
• Ruxolitinib: Incyte Corporation

Polycythemia Vera Drugs Market
JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as the driver mutation of most non-BCR-ABL1 myeloproliferative neoplasms (MPNs). A decade after the beginning of clinical trials, only one JAK inhibitor, Jakafi, has been approved by the US Food and Drug Administration for hydroxyurea-resistant or intolerant Polycythemia Vera patients since 2014. JAKAFI competes with platelet-reducing agents (Anagrelide), Interferon alpha, and BESREMi in the second line of treatment. Even though there are safety concerns regarding JAK inhibitors, we cannot misconstrue the strong uptake of Jakafi in the already treated patients with this blood disorder.

Learn more about the FDA-approved drugs for Polycythemia Vera @ Drugs for Polycythemia Vera Treatment- https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Polycythemia Vera Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
• Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
• Polycythemia Vera Therapeutic Assessment: Polycythemia Vera current marketed and Polycythemia Vera emerging therapies
• Polycythemia Vera Market Dynamics: Polycythemia Vera market drivers and Polycythemia Vera market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Polycythemia Vera Unmet Needs, KOL's views, Analyst's views, Polycythemia Vera Market Access and Reimbursement

Discover more about Polycythemia Vera Drugs in development @ Polycythemia Vera Clinical Trials Assessment- https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Polycythemia Vera Market Report Introduction
2. Executive Summary for Polycythemia Vera
3. SWOT analysis of Polycythemia Vera
4. Polycythemia Vera Patient Share (%) Overview at a Glance
5. Polycythemia Vera Market Overview at a Glance
6. Polycythemia Vera Disease Background and Overview
7. Polycythemia Vera Epidemiology and Patient Population
8. Country-Specific Patient Population of Polycythemia Vera
9. Polycythemia Vera Current Treatment and Medical Practices
10. Polycythemia Vera Unmet Needs
11. Polycythemia Vera Emerging Therapies
12. Polycythemia Vera Market Outlook
13. Country-Wise Polycythemia Vera Market Analysis (2020-2034)
14. Polycythemia Vera Market Access and Reimbursement of Therapies
15. Polycythemia Vera Market Drivers
16. Polycythemia Vera Market Barriers
17. Polycythemia Vera Appendix
18. Polycythemia Vera Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Pulmonary emphysema market- https://www.delveinsight.com/report-store/pulmonary-emphysema-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac implantable electronic devices market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
HIP Replacement devices market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Sepsis market_ https://www.delveinsight.com/report-store/sepsis-market-insight
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Coronary stents market- https://www.delveinsight.com/report-store/stents-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
India:- +91-9650213330

This release was published on openPR.